The LUGANO Study

Status:

Sponsor: EyePoint Pharmaceuticals

Trial Summary

This study is researching an experimental (study) drug called EYP-1901 for people with wet Age-Related Macular Degeneration (wAMD), a condition that can cause loss of central vision due to abnormal blood vessel growth and leakage in the retina. The study is comparing EYP-1901 with aflibercept, an approved treatment for wAMD.

The purpose of this study is to evaluate the effectiveness and safety of EYP-1901 compared with aflibercept in people with wet AMD over a 2-year period. EYP-1901 is a tyrosine kinase inhibitor (TKI) designed to provide long-lasting treatment for wAMD.

The study is also looking at several other research questions, including:

  • How well EYP-1901 controls the signs and symptoms of wet AMD compared with aflibercept
  • How safe and well tolerated EYP-1901 is in people with wet AMD
  • Whether EYP-1901 may help reduce the treatment burden associated with frequent anti-VEGF injections

Condition(s) being studied:​

Exudative AMD

Trial date:

Primary Completion (Estimated)

2026-08

Study Completion (Estimated)

2027-08

Explore Our Active Trials

  • The Izervay Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person’s central vision to worsen. Geographic atrophy is an…

  • The ASP7317 Study

    July 23, 2026

    Sponsor: Astellas Trial Summary Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina – the light-sensitive part at the back of the eye. There are 2 types of…

  • The EVOLVE Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is focused on people with Stargardt disease (STGD) and STGD-like macular dystrophies, inherited retinal conditions that affect the macula and can lead to progressive loss of central vision. STGD is most commonly caused by changes in the ABCA4 gene, while STGD-like conditions are linked…

  • The SIENNA Study

    July 22, 2026

    Sponsor: REGENERON Trial Summary This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition…